Hikma Gains Health Canada Approval for Life-Saving Nasal Spray

Hikma Secures Health Canada Approval for KLOXXADO Nasal Spray

LONDON and GAITHERSBURG, Md. — Hikma Pharmaceuticals PLC has announced that Health Canada has given the green light for KLOXXADO (naloxone HCl) Nasal Spray 8 mg. This critical medication is intended for managing suspected or known opioid overdoses, especially relevant for adult patients dealing with respiratory and/or central nervous system depression brought on by opioid consumption.

What is KLOXXADO?

KLOXXADO delivers an effective dosage of 8 mg of naloxone hydrochloride through a ready-to-use nasal spray. This formulation effectively negates the life-threatening impacts of opioid overdoses, providing immediate assistance until professional medical help can be administered.

“The approval of KLOXXADO Nasal Spray brings a vital option for Canadians grappling with the opioid crisis,” stated Hafrun Fridriksdottir, President of Hikma Generics. “With the alarming rise of perilous synthetic opioids, including illicit fentanyl, having an accessible nasal spray could serve as a pivotal intervention for those affected by overdose situations.”

Sales and Distribution Under Emergent BioSolutions

KLOXXADO will be marketed by Emergent BioSolutions as part of a newly formed six-year agreement with Hikma. As per this arrangement, Emergent will oversee all sales and marketing efforts throughout North America, while Hikma will manufacture KLOXXADO at its production facility in Columbus, Ohio. Emergent aims to have KLOXXADO available by prescription as early as 2026, reaching out to Canadian health agencies and private insurers to facilitate this.

The Urgent Need for Opioid Reversal Options

Paul Williams, SVP and head of products at Emergent, emphasized the gravity of the opioid crisis by noting that in 2023, Canada lost an alarming average of 22 lives daily to opioid overdoses. With medications like NARCAN, which has stood out as a 4 mg naloxone solution, the introduction of KLOXXADO may pave the way for more patients to receive higher dose treatments in emergency situations.

Research from Health Canada indicates a decrease in overdose mortality rates for the past three years, with naloxone distribution cited as a contributing factor. The availability of naloxone kits is vital in reversing thousands of overdoses across the nation. KLOXXADO is anticipated to enhance these efforts, granting healthcare providers and community members another powerful tool in their efforts against opioid-related fatalities.

Understanding Naloxone: The Active Component

Naloxone hydrochloride functions as an opioid antagonist. It competes with opioids at receptor sites, effectively counteracting opioid effects related to respiratory issues, sedation, and hypotension. Its ease of administration and effectiveness has made naloxone a mainstay in opioid overdose treatment protocols within healthcare settings in locations like the United States.

Patient and Community Education

It's essential for individuals who might find themselves in a situation where KLOXXADO is needed to know how to administer it. Family members and caregivers should store KLOXXADO within easy reach and familiarize themselves with its use to allow timely intervention during an opioid overdose emergency. Immediate medical intervention remains crucial even after administering KLOXXADO, as additional medical support may be necessary.

Commitment to Public Health

Hikma Pharmaceuticals has made significant strides in enhancing healthcare access globally for over 45 years, focusing on producing high-quality medicines. With its headquarters in the UK, the company operates across North America, the Middle East, North Africa, and Europe, bringing innovative solutions to the market. The approval of KLOXXADO is a testament to Hikma’s ongoing dedication to tackling public health challenges and providing tools for healthcare professionals and those in crisis.

Contact Information

For further inquiries, individuals may reach out to Steve Weiss, US Communications and Public Affairs at +1 732 788 8279. Alternatively, Assal Hellmer serves as Vice President of Communications and can be contacted for media-related questions.

Frequently Asked Questions

What is KLOXXADO?

KLOXXADO is a naloxone nasal spray designed to treat opioid overdoses by reversing the effects of opioids on the respiratory system.

How does KLOXXADO work?

This medication works by displacing opioids from their receptors in the brain, effectively counteracting respiratory depression and restoring normal breathing.

When will KLOXXADO be available in Canada?

Emergent aims to make KLOXXADO available by prescription in Canada as early as 2026.

Are there any side effects associated with KLOXXADO?

Potential side effects include withdrawal symptoms such as body aches and rapid heartbeat, among others. A full list is provided in the medication guide.

Where can I learn more about Hikma Pharmaceuticals?

More information about Hikma and its commitment to public health can be found on their official website.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.